Arcellx News and Activities

Presence

Arcellx develops cell therapies for cancer and autoimmune diseases. Its products and research services support hospitals, physicians, and patients who need new treatment options.

Arcellx products and services overview:

Cell therapy
Cancer treatments
Autoimmune therapies
Drug research
Clinical development

Revenue: ~$100 million

Employees: 300

Headquarters: Gaithersburg, United States (USA)

Arcellx is owned by Gilead Sciences.

Gilead Sciences is one of the...

Gilead Sciences is a company listed under the stock ticker GILD (US).

Gilead Sciences has a direct presence in 7 countries.

Gilead Sciences has 9 subsidiaries including Arcellx, Gilead Sciences Canada and Gilead Sciences EMEA.

They are in:

Pharmaceuticals50%
Biotechnology50%

Acquisition, funding and merger involving Gilead Sciences.

Gilead Sciences has acquired Arcellx (posted on April 28 2026).

Executives

View the org chart displaying its 31 main executives

Most searched biographies at Arcellx

Popular executive movements at Arcellx

Olivia Ware, Director, has left the company (posted on April 30 2026).
Kristin Myers, Director, has left the company (posted on April 30 2026).
David Lubner, Independent Director, has left the company (posted on April 30 2026).

Click here to view some more movements at Arcellx

Popular executive movements at Gilead Sciences

Diane Wilfong, Chief Accounting Officer and Controller, has left the company (posted on April 21 2026).
Bill Stott, who was Vice President, Global Talent Acquisition, is promoted to Vice President, Human Resources Corporate Functions and Global Talent Acquisition (posted on April 21 2026).
Keeley Wettan has joined the company as Executive Vice President, General Counsel and Compliance (posted on December 18 2025).

Click here to view some more movements at Gilead Sciences

Create your alert
to follow the executive moves at Arcellx.